Chugai: Strong Profits From Cancer Drugs And New Products In 2013
This article was originally published in PharmAsia News
Executive Summary
According to Chugai’s consolidated interim results for December 2013, the company’s anti-cancer drugs and their new osteoporosis drug Edirol saw strong growth domestically.